FDA orphan drug designation for zenocutuzumab and racemetyrosine: A milestone achievement in drug development for advanced pancreatic cancer
Biogen has entered into a binding agreement with Denali Therapeutics to jointly develop and commercialise therapeutics for Parkinson’s disease.
MePIS OPEX is a cutting-edge software solution that forms the basis for improvements in productivity in the life science production.
US-based Ovid’s Angelman syndrome drug OV101 is currently in the late stages of a Phase III trial. With an approval on the horizon, Ovid has signed a partnership with Angelini to mirror existing US commercialisation preparations for the European market. What promise does OV101 have for at-need Angelman syndrome patients?
AstraZeneca has entered into an agreement with UK-based biotechnology company Redx Pharma to licence a porcupine inhibitor, named RXC006, for fibrotic diseases.
Solid tumour personalised immunotherapy company Imvax has raised $112m in a Series C funding round. How can Imvax’s multi-specific antigen approach improve survival for glioblastoma patients?
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics’ proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa’s proprietary Endoxifen.
The Covid-19 pandemic is a truly global health emergency, and one that will not end unless drugs and vaccines to tackle the deadly viral disease are available to everyone that needs them. This is a lot easier said than done. Allie Nawrat investigates pricing and allocation challenges and solutions that are required to tackle the logistics in ending a worldwide pandemic.
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.